McCann FitzGerald are acting as Irish counsel to Horizon Pharma plc in relation to its proposed acquisition of Hyperion Therapeutics, Inc. for $46.00 per Share or $1.1 billion in cash.
Contacts
Ben Gaffikin, Partner
Joe Fay, Partner
Matter Type
M&A: Acquiror's Counsel
Industry
Healthcare, Life Sciences & Chemicals
News Category
M&A